Thursday - April 9, 2026
Nubeqa (darolutamide) Receives Third Approval in China for Men With Advanced Prostate Cancer
February 04, 2026
LEVERKUSEN, Germany, Feb. 4 -- Bayer, a pharmaceutical and life sciences company, issued the following news release on Feb. 3, 2026:

* * *

Nubeqa (darolutamide) receives third approval in China for men with advanced prostate cancer

Darolutamide is now the first and only androgen receptor inhibitor (ARi) approved in China for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy ( . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products